2-(QUINUCLIDIN-3-YL)PYRIDO[4,3-B]INDOL-1-ONES AND ISOQUINOLIN-1-ONES - POTENT CONFORMATIONALLY RESTRICTED 5-HT(3) RECEPTOR ANTAGONISTS

被引:102
作者
CLARK, RD
MILLER, AB
BERGER, J
REPKE, DB
WEINHARDT, KK
KOWALCZYK, BA
EGLEN, RM
BONHAUS, DW
LEE, CH
MICHEL, AD
SMITH, WL
WONG, EHF
机构
[1] SYNTEX INC,INST PHARMACOL,PALO ALTO,CA 94304
[2] SYNTEX INC,INST ANALYT RES,DEPT MOLEC STRUCT,PALO ALTO,CA 94304
关键词
D O I
10.1021/jm00070a008
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
引用
收藏
页码:2645 / 2657
页数:13
相关论文
共 72 条
  • [1] CONFORMATIONAL-ANALYSIS .130. MM2 - HYDROCARBON FORCE-FIELD UTILIZING V1 AND V2 TORSIONAL TERMS
    ALLINGER, NL
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1977, 99 (25) : 8127 - 8134
  • [2] FACILE SYNTHESIS OF ETHYNYLATED BENZOIC-ACID DERIVATIVES AND AROMATIC-COMPOUNDS VIA ETHYNYLTRIMETHYLSILANE
    AUSTIN, WB
    BILOW, N
    KELLEGHAN, WJ
    LAU, KSY
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 1981, 46 (11) : 2280 - 2286
  • [3] THE DIFFERENTIAL ACTIVITIES OF R(+)-ZACOPRIDE AND S(-)-ZACOPRIDE AS 5-HT3 RECEPTOR ANTAGONISTS
    BARNES, JM
    BARNES, NM
    COSTALL, B
    DOMENEY, AM
    JOHNSON, DN
    KELLY, ME
    MUNSON, HR
    NAYLOR, RJ
    YOUNG, R
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 37 (04) : 717 - 727
  • [4] BASHA A, 1977, TETRAHEDRON LETT, P4171
  • [5] 5-HYDROXYTRYPTAMINE (5-HT3) RECEPTOR ANTAGONISTS .1. INDAZOLE AND INDOLIZINE-3-CARBOXYLIC ACID-DERIVATIVES
    BERMUDEZ, J
    FAKE, CS
    JOINER, GF
    JOINER, KA
    KING, FD
    MINER, WD
    SANGER, GJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (07) : 1924 - 1929
  • [6] 5-HYDROXYTRYPTAMINE (5-HT3) RECEPTOR ANTAGONISTS .2. 1-INDOLINECARBOXAMIDES
    BERMUDEZ, J
    DABBS, S
    JOINER, KA
    KING, FD
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1990, 33 (07) : 1929 - 1932
  • [7] NOVEL ANTAGONISTS OF THE 5-HT3 RECEPTOR - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF (2-ALKOXYBENZOYL) UREAS
    BRADLEY, G
    WARD, TJ
    WHITE, JC
    COLEMAN, J
    TAYLOR, A
    RHODES, KF
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1992, 35 (09) : 1515 - 1520
  • [8] PHARMACOLOGICAL PROPERTIES OF GR38032F, A NOVEL ANTAGONIST AT 5-HT3 RECEPTORS
    BUTLER, A
    HILL, JM
    IRELAND, SJ
    JORDAN, CC
    TYERS, MB
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1988, 94 (02) : 397 - 412
  • [9] CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
  • [10] N-(QUINUCLIDIN-3-YL)-1,8-NAPHTHALIMIDES WITH 5-HT(3) RECEPTOR ANTAGONIST AND 5-HT(4) RECEPTOR AGONIST PROPERTIES
    CLARK, RD
    WEINHARDT, KK
    BERGER, J
    LEE, CH
    LEUNG, E
    WONG, EHF
    SMITH, WL
    EGLEN, RM
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (06) : 1375 - 1378